Novo Nordisk Offers €2.6bn For Ablynx
Executive Summary
Danish diabetes drug specialist Novo Nordisk has offered €2.6bn in cash to acquire Ablynx. The Belgian firm is playing hard to get: this is the second offer from Novo but it is still refusing to talk.
You may also be interested in...
Biopharma Quarterly Deal-making Statistics, Q4 2017
Biopharma financing finished off 2017 strong with a total value of $14.5 billion in Q4, led again by FOPOs. CVS' massive $77 billion acquisition of Aetna resulted in an all-time quarterly high in the M&A category, and the largest alliances were dominated by the development of vaccines and antibodies.
Novo Outbid As Sanofi Agrees €3.9bn Ablynx Acquisition
Sanofi is to acquire Belgian nanobody developer Ablynx in an all-cash deal worth €3.9bn, 50% higher than the spurned bid by Novo Nordisk.
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.